|
Apr 18
|
Stocks to watch this week: Tesla, Alphabet, Intel, Boeing and Unilever
|
|
Apr 18
|
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
|
|
Apr 17
|
Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?
|
|
Apr 17
|
Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
|
|
Apr 16
|
Bristol Myers Squibb (BMY) Stock Moves -1.35%: What You Should Know
|
|
Apr 16
|
Is Bristol-Myers Squibb Company (BMY) The Dirt Cheap Stock To Invest In Now?
|
|
Apr 16
|
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News
|
|
Apr 16
|
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?
|
|
Apr 15
|
BMS’ Camzyos flops in Phase III non-obstructive hypertrophic cardiomyopathy trial
|
|
Apr 15
|
Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy for Long Term Growth?
|
|
Apr 15
|
BMY Down on Heart Drug Camzyos Failure in Late-Stage Study
|
|
Apr 15
|
Bristol-Myers Squibb Company (BMY): Among the Best Value Dividend Stocks to Buy According to Billionaires?
|
|
Apr 15
|
Bristol Myers stumbles in bid to widen heart drug’s use
|
|
Apr 14
|
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It
|
|
Apr 14
|
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
|
|
Apr 14
|
BMS’ Opdivo combo approved in US for hepatocellular carcinoma
|
|
Apr 11
|
Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market
|
|
Apr 11
|
Is Bristol-Myers Squibb Company (BMY) One of the Best Medical Stocks to Buy According to Billionaires?
|
|
Apr 11
|
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
|
|
Apr 11
|
Bristol-Myers Squibb Investors Likely to Focus on Performance of New Schizophrenia Therapy, UBS Says
|